The benefits of endovascular repair of ruptured abdominal aortic aneurysm remain controversial, without any strong evidence about advantages in specific subgroups. 
Introduction
There have been four randomized trials of endovascular versus open repair of ruptured abdominal aortic aneurysm (AAA), all with the intention of showing the superiority of endovascular aneurysm repair (EVAR). The first trial was a single-centre pilot trial of 32 patients conducted in Nottingham, UK, between 2002 and 2004 ; the 30-day mortality rate was 53 per cent in each treatment group 1 . Following this, two further trials of similar design were developed in the Amsterdam area of the Netherlands (Amsterdam Acute Aneurysm, AJAX trial) and in France (Endovasculaire versus Chirurgie dans les Anévrysmes Rompus, ECAR trial); patients were considered for randomization only if their aortic anatomy was suitable for EVAR. The sample sizes of these trials were informed by systematic reviews 2, 3 of observational series that showed a strong benefit in operative mortality for EVAR compared with open repair. The Amsterdam trial 4 randomized 116 patients and failed to show any benefit for EVAR with respect to either the primary endpoint (combined 30-day morbidity and mortality) or 30-day mortality. The French trial 5 randomized 107 patients and again failed to show any significant difference in 30-day mortality between the randomized groups. The last trial to start (Immediate Management of the Patient with Ruptured Aneurysm: Open Versus Endovascular repair, IMPROVE trial), and the largest, was in the UK (with 1 Canadian centre), but was based on a different design, with patients being randomized at the point of clinical diagnosis of ruptured aneurysm to an endovascular strategy (EVAR if found anatomically suitable on subsequent CT, open repair if not) versus open repair; this trial was designed to have more than 90 per cent power to detect a 14 per cent difference in 30-day mortality with recruitment of 600 patients. Even with 613 patients, IMPROVE 6 failed to show a 30-day mortality benefit for the endovascular strategy, partly owing to a lower mortality rate than anticipated in the open repair group. It was large enough to allow limited subgroup analysis 6 . An editorial commentary 7 accompanying publication of this trial suggested that the sample size calculations might have been too optimistic and that, given the advances in intensive therapy, 90-day survival should have been chosen as the primary outcome. For patients, and their families, the most important outcome is reaching home alive, not 30-day mortality.
To counter some of these criticisms and permit more robust subgroup analyses, the ruptured aneurysm trialists agreed to collaborate to allow an individual-patient meta-analysis of outcomes to 90 days after rupture. Given the different trial designs, an individual-patient approach has the added advantage of pooling data from similar groups of patients, for example by selecting out those anatomically suitable for EVAR from the IMPROVE trial for comparison with patients from the AJAX and ECAR trials.
Unfortunately, the data from the Nottingham trial could not be retrieved, so this meta-analysis is based on the data from the AJAX 4 , ECAR 5 and IMPROVE 6 trials only. The purpose was to test the hypotheses that, particularly for patients anatomically suitable for EVAR, endovascular repair offers an improvement in 90-day survival and earlier hospital discharge compared with open repair, as well as identifying whether specific subgroup analyses by age, sex and Hardman index (a validated morbidity score for ruptured aneurysm 8, 9 ) had better 90-day survival with EVAR. In addition, the meta-analysis presents 30-day outcomes, including whether morphological features affected 30-day mortality and whether abdominal compartment syndrome was more common after EVAR than open repair.
Methods
The methods for the three trials included in this meta-analysis have been published previously 10 -12 The three data sets were merged based on fields available in the case record forms of the largest trial (IMPROVE), range checks were conducted and queries resolved with the individual trial coordinating centres.
Statistical analysis
The primary analyses considered the groups as randomized within each trial, irrespective of the different trial designs. Mortality was assessed at both 30 and 90 days after randomization (for IMPROVE) and following admission (for AJAX and ECAR), with 90-day survival being the primary outcome of interest. The odds ratio for both 30-and 90-day mortality for the endovascular strategy or EVAR versus open repair was estimated using logistic regression, adjusting for trial to obtain a one-stage fixed-effect pooled estimate. A secondary analysis was conducted by estimating the odds ratio separately within each study and then pooling using random-effects meta-analysis, with between-study heterogeneity estimated using a method of moments 13 . The proportion of between-trial variability beyond that expected by chance was quantified using the I 2 statistic 14 . Analyses were then repeated for odds ratios estimated from logistic regression models adjusted for age, sex and Hardman index. Multiple imputation using chained equations was used to account for missing baseline co-variables in adjusted analyses (Appendix S1, supporting information) 15 .
Secondary analyses were conducted with the purpose of making the groups in the different trials more homogeneous. Only those patients with a final diagnosis of ruptured AAA and considered suitable for EVAR were retained in the analyses. For AJAX and ECAR, suitability for EVAR was a prerequisite for inclusion in the trial. For the IMPROVE trial, suitability for EVAR was defined as either local CT assessment of suitability or, if not assessed locally, a 'within liberal instructions for use' definition from a core laboratory CT analysis was used.
Kaplan-Meier survival plots and cumulative incidence of time to primary hospital discharge were produced by randomized group within each trial separately and accompanied by a log rank test. A Cox proportional hazards model was used to assess whether the randomized groups differed in terms of the cause-specific hazard of primary hospital discharge (competing in-hospital mortality not withstanding).
The subgroups age, sex and Hardman index were assessed for differences in the effect of the endovascular and open strategies by including an interaction term between the subgroup and randomized group in a logistic regression model.
The reporting of complications and reinterventions was very different in the three trials, but they all reported on the use of occlusion balloons and the incidence of abdominal compartment syndrome and other non-occlusive mesenteric hypoperfusion syndromes 16 ; however, the abdominal compartment syndrome data for the AJAX trial were collected retrospectively.
The effect of aortic morphology on 30-day mortality was also assessed within each trial for AAA diameter, aortic neck diameter, aortic neck length and proximal neck α angulation. Because these analyses are not a comparison between randomized groups, all analyses were adjusted for the following potential confounding factors: age, sex (AJAX and IMPROVE), Hardman index, admission mean arterial BP, treatment commenced and randomized group (IMPROVE only). Analysis of each morphological variable was conducted both adjusted and unadjusted for the other three morphological variables. (27) 108 (30) 81 ( Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) and †median (i.q.r.). ‡Suitability for endovascular aneurysm repair (EVAR) in IMPROVE defined by local assessment of suitability if available; otherwise a core laboratory assessment of 'within liberal instructions for use' was used to define suitability. Suitability not assessed in 46 ruptured abdominal aortic aneurysms (rAAAs) in IMPROVE and one in ECAR. §Mean arterial BP recorded only in ECAR; for AJAX and IMPROVE it was approximated by 2/3 diastolic + 1/3 systolic BP. ¶IMPROVE and ECAR measured top neck diameter; AJAX measured maximum neck diameter. (7) 12 (21) 136 (74⋅7) Tube/other ‡ 4 (7) 1 (2) 7 (3⋅8) Open repair commenced n = 57 (2) 10 (2⋅6) Length of stay for those discharged n = 84 n = 75 n = 384 alive (days)* 14 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) 15 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) 11 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Values in parentheses are percentages unless otherwise indicated; *values are median (i.q.r. 
Results
The baseline characteristics of the 836 patients are shown in Table 1 . Because the design of the IMPROVE trial was different from that of the other two trials, the number of patients with ruptured aortoiliac aneurysm (core laboratory diagnosis) who were anatomically suitable for EVAR is shown. The one patient in ECAR who did not have direct aneurysm repair underwent axillobifemoral bypass. The demographic details are shown for all 836 patients randomized. The patients in IMPROVE tended to be older, with more women included, and patients had larger aneurysms.
The operative details and discharge data for the patients are shown in Table 2 . Both AJAX and ECAR used predominantly aortouni-iliac endografts, which restricted completion of the procedure, with femorofemoral cross-over grafts, under local anaesthesia. The in-hospital mortality rate was higher for IMPROVE (37⋅4 per cent) than for either AJAX (27⋅6 per cent) or ECAR (27⋅9 per cent) but, for those discharged alive, patients in IMPROVE were discharged sooner and more often directly to home. Overall survival to 90 days is shown in Fig. 1 .
At 90 days there was slight evidence of heterogeneity in the odds ratios (I 2 =18⋅9 per cent), with the odds ratio in ECAR being lower than in the other trials, although several patients in this trial had been lost to follow-up (Fig. 2a) . Despite this, the overall pooled odds ratio for survival at 90 days was not significant (0⋅85, 95 per cent c.i. 0⋅64 to 1⋅13), with a random-effects estimate of 0⋅82 (0⋅56 to 1⋅18). Adjusted analyses gave similar results and those that restricted the population to ruptured aneurysms suitable for EVAR were more homogeneous (pooled odds ratio 0⋅74, 0⋅51 to 1⋅08) (Fig. 2b) . Similar results were seen at 30 days, with little evidence of a benefit of an endovascular strategy or EVAR among any of the three trials comparing patients as randomized (Fig. S1a, supporting information) , and estimated only in patients with confirmed rupture and aortic anatomy suitable for EVAR (Fig. S1b, supporting information) .
There was also little evidence of the treatment effect changing by age or Hardman index at either 30 days (Fig. S2, supporting information) or 90 days (Fig. 3) . However, for age, 90-day results were heterogeneous across the trials (I 2 = 74⋅2 per cent, P = 0⋅021), with AJAX suggesting a benefit of open repair and ECAR suggesting a benefit of EVAR for older patients. There were no early deaths among women in the ECAR trial. In the pooled analysis, women benefited more from an endovascular strategy than men (ratio of odds ratios 0⋅49, 95 per cent c.i. 0⋅24 to 0⋅99). A similar ratio of odds ratios was estimated at 30 days (0⋅47, 0⋅23 to 0⋅97).
Although the IMPROVE trial had suggested that the 30-day mortality for open repair was higher when patients were randomized outside routine working hours, this finding could not be substantiated across the three trials.
Occlusion balloons were not used widely, but were employed more often in ECAR (18 of 107, 16⋅8 per cent), than in either AJAX (4 of 116, 3⋅4 per cent) or IMPROVE (32 of 522, 6⋅1 per cent). The reporting of complications was very different in the three trials; however, abdominal hypoperfusion syndromes (including abdominal compartment syndrome) were reported in all trials ( Table 3) . Only ECAR routinely reported abdominal compartment syndrome according to established methods 17 and searched actively for colonic ischaemia, perhaps explaining the higher rates reported in this trial. Abdominal compartment syndrome was reported more often in the EVAR groups of AJAX and ECAR, but not in the endovascular strategy group of IMPROVE (pooled odds ratio 1⋅64, 95 per cent c.i. 0⋅87 to 3⋅09). However, in all trials there was (9) 2 of 57 (4) 2 of 59 (3) 5 of 59 (8) ECAR ACS CMI 8 of 56 (14) 4 of 56 (7) 1 of 51 (2) 8 of 51 (16) an indication of a lower incidence of isolated mesenteric and/or colonic ischaemia in the endovascular strategy or EVAR groups; the pooled odds ratio (0⋅57, 0⋅32 to 1⋅01) narrowly failed to achieve statistical significance.
There was wide variation in discharge policy across the three trials, with many patients in ECAR being discharged to other care facilities, whereas more patients in IMPROVE were discharged directly to home. Overall, for patients discharged alive from the vascular surgical centre, the duration of primary hospital stay was shorter for patients in the endovascular strategy or EVAR groups (pooled hazard ratio for discharge 1⋅24, 95 per cent c.i. (Fig. 4; Fig. S3, supporting  information) .
The morphological parameters for aneurysms in the three trials are shown in Table 1 . Patients in IMPROVE had larger aneurysm diameters and a very different distribution of aneurysm neck lengths compared with the other trials (Fig. S4, supporting information) . As previously observed for the IMPROVE trial 18 , aneurysm neck length (Fig. 5) , but not AAA diameter, neck diameter or proximal neck angle (Figs. S5-S7, supporting information) , appeared to be a predictor of 30-day mortality, particularly after open repair. For open repair, for each 15-mm increase in neck length, 30-day mortality decreased (odds ratio 0⋅69, 95 per cent c.i. 0⋅53 to 0⋅89); with both operations combined the association was slightly weaker (odds ratio 0⋅80, 0⋅66 to 0⋅97).
Discussion
The best evidence comes from synthesis of the results of randomized trials. Three recent randomized trials of endovascular versus open repair of ruptured AAA showed no significant survival benefit at 90 days for endovascular repair (pooled odds ratio 0⋅85, 95 per cent c.i. 0⋅64 to 1⋅13), but with slight heterogeneity. Perhaps the heterogeneity was expected given that the trials had very different designs, although estimating the extent of between-study heterogeneity is difficult with only three trials 19 . The additional flexibility of individual-patient meta-analysis also allowed only specific patient subsets to be included in the meta-analysis. For instance, when the analysis included only those patients in IMPROVE with confirmed rupture eligible for both treatments, as in the AJAX and ECAR trials, at 90 days the trial odds ratios were more homogeneous and the pooled odds ratio was lower, but with a wider confidence interval (0⋅74, 95 per cent c.i. 0⋅51 to 1⋅08) because a smaller number of patients contributed to this analysis. Similarly, at 30 days there was no evidence that EVAR offered a survival advantage in patients with confirmed rupture eligible for both endovascular and open repair.
Another benefit of an individual-patient meta-analysis is the ability to identify subgroups of patients who may benefit from a specific treatment. Women appeared to be under-represented in both the ECAR and AJAX trials, so the estimate of the influence of sex was dominated by the larger IMPROVE trial. Women appear to gain twice as much benefit from an endovascular strategy or EVAR versus open repair than men, although the pooled effect was of borderline significance. The reasons for this potential benefit in women are still uncertain, although morphology may play a role 18 . This begins to suggest that, although further research is needed, EVAR should be a more common treatment option for women. The weak trend for patients with higher Hardman index (more unfit) to have better 30-day survival after EVAR was not substantiated across the three trials and there was no clear effect of age.
The three trials were set in different healthcare systems, as clearly shown by the time to discharge and destination after discharge. Patients in France and the Netherlands stayed in hospital longer and were more often discharged to a step-down care facility than patients in IMPROVE, where more patients were discharged directly to home. Nevertheless the time to discharge was shorter in the endovascular strategy or EVAR groups. In contrast, for each trial, it took longer to get a patient to EVAR than to open repair, the difference being greatest in France. This too is likely to be a reflection of both the stability of the patient, with ECAR having the most stable patients, and the different healthcare organizations. There is weak evidence that delays in time to treatment influence survival adversely 20, 21 . The longer time taken to start definitive EVAR could have contributed to some of the anticipated benefit of endovascular repair on 30-day mortality being eroded.
The specificity of CT for the detection of ruptured AAA has been questioned 22 . In the AJAX trial three patients who underwent open repair were found to have an intact AAA but a different pathology, such as bleeding liver tumour or Crohn's disease. At endovascular repair, the underlying cause of admission might not have been ascertained correctly in a few patients, potentially increasing the mortality of those in the EVAR/endovascular strategy groups.
The largest trial, IMPROVE, also conducted cohort analyses and two of the observations reported were assessed in individual patients from the three trials. The findings from IMPROVE included the observation of higher mortality risk for open repair outside routine working hours 23 and the strong influence of aneurysm neck length on mortality after open repair 18 . Overall there was no evidence for a higher mortality rate among patients treated outside routine working hours. The strong relationship between short aneurysm neck length and high mortality after open repair may help explain why the mortality rate after open repair remains high; around one-quarter of the patients contributed by the IMPROVE trial had a juxtarenal aneurysm (aneurysm neck length 0-9 mm) and were not eligible for conventional EVAR. Open juxtarenal aneurysm repair requires cross-clamping of the aorta above the renal arteries, with inevitable compromise of the visceral circulation, especially in shocked patients. In contrast, for longer aneurysm necks (15 mm or more), an infrarenal aortic clamp is likely to be used for open repair, with operative mortality similar to that for EVAR 18 . In the future, the reporting of results for open repair of ruptured AAA should be in two categories: infrarenal aneurysms and juxtarenal aneurysms.
Some other clinical messages are consistent across all three trials. The reported rate of abdominal compartment syndrome was low, similar to the 8 per cent reported in a recent meta-analysis 24 , and only the ECAR trial suggested a higher rate after EVAR. Abdominal compartment syndrome is characterized by intra-abdominal hypertension. As bladder pressures were measured only in the ECAR trial, underdetection of abdominal compartment syndrome is likely. However, other non-occlusive mesenteric hypoperfusion syndromes are recognized, including mesenteric and colonic ischaemia, and these tended to be more common after open repair 16 . The total rate of non-occlusive hypoperfusion complications reported was much higher than the 8 per cent noted for abdominal compartment syndrome.
This individual-patient meta-analysis across three European trials concluded that there is no early survival benefit for an endovascular strategy or EVAR following ruptured AAA, although there is a very weak indication in favour of EVAR at 90 days for patients with ruptured AAA, who are eligible for both treatments. The meta-analysis continues to suggest that women may have improved early survival with an EVAR/endovascular strategy and that patients in the endovascular strategy or EVAR groups benefit from earlier hospital discharge. These data might be sufficient for patients to prefer EVAR, but longer-term data from all three trials will be needed to inform clinical decision-making.
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